Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Mary E. Dillhoff

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6589-7072; OpenAlex author ID A5010019978, A5030505421, A5089248263, A5089791227. Sources: ClinicalTrials.gov.

Their work

Papers
41 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
180
Papers, trials and grants by year

2017: 4 papers · 2018: 3 papers · 2019: 5 papers, 1 trial · 2020: 6 papers · 2021: 5 papers · 2022: 5 papers · 2023: 1 paper · 2024: 5 papers · 2025: 4 papers · 2026: 3 papers

Papers 41

  1. Fragmented Care for Pancreatic Cancer Patients at a High-Volume Surgical Center. Co-author DOI 10.1016/j.jss.2026.03.035↗
  2. Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Databas… Co-author DOI 10.14701/ahbps.25-209↗
  3. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  4. Variation in lymph node assessment after pancreatic cancer resection: Patient, surgeon, pathologist, or hospital? Co-author DOI 10.1016/j.amjsurg.2024.116067↗
  5. Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Co-author DOI 10.1016/j.hpb.2025.08.015↗
  6. Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.1097/xcs.0000000000001277↗
  7. Impact of Frailty on the Outcomes of Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17244030↗
  8. Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27558↗
  9. Association between social determinants of health and delayed postoperative adjuvant therapy among patients undergoing resection of pancreatic cancer. Co-author DOI 10.1002/jso.27571↗
  10. Association between quality metric adherence and overall survival among patients undergoing resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.04.043↗
  11. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  12. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  13. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals. Co-author DOI 10.1245/s10434-023-13230-y↗
  14. Identification of circulating plasma ceramides as a potential sexually dimorphic biomarker of pancreatic cancer-induced cachexia. First author DOI 10.1002/rco2.68↗
  15. Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis. Co-author DOI 10.1007/s11605-022-05380-3↗
  16. Patterns of health care utilization among Medicare beneficiaries diagnosed with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2021.10.027↗
  17. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Co-author DOI 10.1093/bjs/znac354↗
  18. The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. Co-author DOI 10.3390/ijms23137066↗
  19. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.08.002↗
  20. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic can… Co-author DOI 10.1016/j.radonc.2021.02.035↗
  21. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
  22. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. Co-author DOI 10.3748/wjg.v27.i27.4383↗
  23. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  24. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgic… Co-author DOI 10.1002/cam4.3075↗
  25. Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25861↗
  26. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. Co-author DOI 10.1016/j.hpb.2020.01.013↗
  27. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Co-author DOI 10.18632/oncotarget.27496↗
  28. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. Co-author DOI 10.3390/jcm9041129↗
  29. Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2019.7380↗
  30. Hospice utilization among Medicare beneficiaries dying from pancreatic cancer. Co-author DOI 10.1002/jso.25623↗
  31. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  32. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  33. The Impact of Dedicated Cancer Centers on Outcomes Among Medicare Beneficiaries Undergoing Liver and Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-019-07677-1↗
  34. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  35. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. Co-author DOI 10.1002/jcsm.12251↗
  36. Exosomes in Pancreatic Cancer: from Early Detection to Treatment. Last author DOI 10.1007/s11605-018-3693-1↗
  37. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemo… Co-author DOI 10.1097/coc.0000000000000452↗
  38. Hospital Volume and the Costs Associated with Surgery for Pancreatic Cancer. Co-author DOI 10.1007/s11605-017-3479-x↗
  39. Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. Co-author DOI 10.1097/mpa.0000000000000898↗
  40. Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature. Co-author DOI 10.18632/oncotarget.20277↗
  41. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗

Trials 1

  1. Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer Principal investigator NCT03711890↗

Closest collaborators

The 25 strongest of 180 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Timothy Michael Pawlik · 26 shared papers, 2017–2026 · strength 4.12
  2. Jordan M. Cloyd · 23 shared papers, 2019–2026 · strength 3.72
  3. Aslam M. Ejaz · 20 shared papers, 2019–2026 · strength 3.26
  4. Allan Tsung · 10 shared papers, 2019–2022 · strength 1.21
  5. Anne M. Noonan · 8 shared papers, 2019–2026 · strength 1.19
  6. Ashish Manne · 5 shared papers, 2024–2026 · strength 1.02
  7. Terence Marques Williams · 9 shared papers, 2017–2022 · strength 0.97
  8. Muhammad Musaab Munir · 4 shared papers, 2023–2025 · strength 0.92
  9. Eric David Miller · 5 shared papers, 2020–2025 · strength 0.83
  10. Shafia Rahman · 4 shared papers, 2024–2026 · strength 0.79
  11. Diamantis I. Tsilimigras · 6 shared papers, 2019–2024 · strength 0.78
  12. J. Madison Hyer · 5 shared papers, 2019–2022 · strength 0.62
  13. Yutaka Endo · 3 shared papers, 2023–2024 · strength 0.62
  14. Patrick L. Quinn · 2 shared papers, 2026 · strength 0.62
  15. Laith I. Abushahin · 4 shared papers, 2020–2026 · strength 0.58
  16. Muhammad Muntazir Mehdi Khan · 2 shared papers, 2024–2025 · strength 0.51
  17. Anghela Z. Paredes · 5 shared papers, 2018–2021 · strength 0.50
  18. Zayed Rashid · 2 shared papers, 2024 · strength 0.47
  19. Patrick W. Underwood · 2 shared papers, 2025 · strength 0.45
  20. Andrew H. Ko · 5 shared papers, 2017–2026 · strength 0.43
  21. Adam R. Wolfe · 4 shared papers, 2020–2021 · strength 0.43
  22. Brian G. Czito · 4 shared papers, 2017–2026 · strength 0.38
  23. Noelle K. LoConte · 4 shared papers, 2017–2026 · strength 0.38
  24. Robert A. Wolff · 4 shared papers, 2017–2026 · strength 0.38
  25. Courtney L. Scaife · 4 shared papers, 2017–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.